Amwell, Inc. (NYSE: AMWL, $13,02, +165.07% YTD)) is quietly scripting one of Wall Street’s more intriguing digital‑health turnarounds—an AI‑infused, platform‑first story backed by a management bench that looks more like a health‑tech all‑star team than a typical telehealth cast.
Digital Care, Rewritten…
Beef is getting pricier just as biotech is getting hotter, and for investors willing to look past the grocery aisle to the lab bench, that may be the more interesting inflation story.
From Ribeye Shock to Risk-On: The Macro Backdrop
Consumers may…
Butterfly Network’s (BFLY) Midjourney cameo now sits inside a bigger, more nuanced script: AI‑driven imaging that can delight investors, unnerve ethicists, and occasionally confuse radiologists—all while telehealth platforms like Amwell (AMWL) quietly wire the whole thing into everyday care. The result is…
In a world where investors handicap everything from rate cuts to chip cycles, a quieter thesis is gaining traction: exposure to actual trees may be as material to human performance as exposure to Treasury yields. A growing body of research in leading…
In a quarter where the market preferred flashy AI tickers to unglamorous healthcare plumbing, P3 Health Partners (PIII) and Amwell (AMWL) quietly reported results that suggest the real work in healthcare is happening far from meme stocks and momentum screens. Both companies…
Amwell’s (NYSE: AMWL) first-quarter scorecard reads like a classic Wall Street turnaround chapter: the top line is shrinking, but the balance sheet is fortified, losses are tightening, and management is whistling its way toward cash-flow breakeven by year-end.
Cash, Costs and a…
Amwell (AMWL, $6.42) is preparing to unveil its first quarter 2026 operating results on May 5, marking a critical checkpoint in the Boston-based telehealth platform's journey toward operational cash flow breakeven. Analysts anticipate revenue of approximately $51.5 million for the quarter, with…
